How to Read an S-1 Filing: A Practical Guide to US IPO Prospectuses

The SEC’s December 2024 adoption of the Electronic Filing Modernization Rule (EDGAR Next) — mandating structured, machine-readable filing formats for all registration statements effective 1 January 2026 — has fundamentally altered the reading protocol for S-1 filings. For Hong Kong-based sponsors, family offices, and cross-border investors who routinely compare HKEX prospectuses (governed by the Companies (Winding Up and Miscellaneous Provisions) Ordinance, Cap. 32, and the SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC) against US IPO disclosures, the shift from narrative-heavy PDFs to XBRL-tagged, data-queryable documents is not merely a compliance upgrade. It is a structural change in how risk, revenue recognition, and corporate governance are surfaced. This guide breaks down the S-1 into its four functional layers — executive summary, risk factors, financial disclosures, and corporate structure — using the analytical framework a Hong Kong practitioner would apply to a Main Board prospectus, but calibrated for the US disclosure regime under the Securities Act of 1933 and SEC Regulation S-K.

The Executive Summary and Prospectus Summary

The “Front Door” as a Legal Trap

The prospectus summary (Item 1 of Form S-1, per Regulation S-K Item 503) is the most densely packed section by litigation risk. Unlike a Hong Kong prospectus where the “Summary” section under the Companies Ordinance must present a “fair and accurate” overview but carries no standalone liability (the prospectus as a whole is the operative document), the US summary is explicitly subject to anti-fraud provisions under Section 12(a)(2) of the Securities Act. Any materially misleading statement in the summary — even if corrected elsewhere — creates a private right of action for purchasers.

Hong Kong readers should note that the US summary typically includes the offering size in two tranches: the primary offering (shares sold by the company) and the secondary offering (shares sold by existing shareholders). The split between primary and secondary proceeds is a direct indicator of insider liquidity intent. A primary-to-secondary ratio below 1.0x — meaning more existing shares are being sold than new capital raised — flags potential insider de-risking, a dynamic rarely seen in HKEX Main Board IPOs where secondary sales are capped at 50% of the offering under Listing Rule 8.08(1).

Use of Proceeds as a Strategic Signal

Item 4 of the S-1 (Use of Proceeds) must be stated with “specificity” under Regulation S-K Item 504. Unlike HKEX’s more flexible approach (Listing Rule 11.07 allows general categories like “working capital”), the SEC requires a percentage breakdown for each material use. A Hong Kong analyst should flag three patterns:

• No specific acquisition target named: If the company allocates more than 20% to “acquisitions” without identifying a target, this is a soft warning that proceeds may be deployed opportunistically or for stock-based M&A.
• Debt repayment exceeding 30%: This suggests the IPO is a refinancing event, not a growth capital raise. The S-1 must disclose the interest rate, maturity, and lender identity for the debt being repaid (Item 4(b)).
• R&D allocation below 10% for a biotech or tech company: This contradicts the narrative in the business section and warrants cross-referencing with the risk factors on product pipeline viability.

Risk Factors: The Hong Kong-to-US Calibration

Item 105 and the “Materiality” Threshold

The risk factors section (Item 105 of Regulation S-K) is the single longest section in any S-1, often running 40-60 pages. Hong Kong practitioners accustomed to the SFC’s “Material Risk Factors” requirement under the Code of Conduct (Paragraph 16.2) — which mandates risks be “specific to the issuer and its industry” — will find the US regime both broader and more formulaic.

The SEC’s 2020 modernization rule eliminated the requirement to list risks in order of importance. As a result, most S-1s now present risks in a standardised taxonomy: industry risks, company risks, regulatory risks, and offering-specific risks. The analytical shortcut is to read only the first 10 risk factors and the last 5. The first 10 typically contain the company’s most material legal and business exposures (the SEC staff pushes for these to be “front-loaded”). The last 5 often contain the “boilerplate” risks — market volatility, shareholder dilution, absence of dividend policy — that are nearly identical across all S-1s.

The China-Specific Risk Factor (Item 105(c))

For Hong Kong investors evaluating Chinese companies listing via the US-China audit cooperation framework (PCAOB access, effective 2022), the critical sub-section is Item 105(c) — “Risks Related to Doing Business in the People’s Republic of China.” The SEC’s December 2021 guidance (Release No. 33-11001) requires these companies to disclose, in a separate section, the specific regulatory approvals required from the CSRC, the NDRC, and the Ministry of Commerce for the offshore offering. The S-1 must also state whether the company’s VIE structure (if applicable) has been reviewed by the CSRC under the July 2021 Data Security Law and the January 2022 Cybersecurity Review Measures.

A Hong Kong sponsor should verify that the S-1 includes an explicit statement that “the company is not required to obtain approval from the CSRC for this offering” or, if required, that the approval has been obtained and filed as an exhibit. Any ambiguity here is a red flag — the SEC has issued at least 18 comment letters since January 2023 specifically requesting clarification on CSRC approvals for China-domiciled issuers.

Financial Disclosures and MD&A

The Three-Year Audit Rule and Reconciliation

Item 6 of the S-1 (Selected Financial Data) requires audited financial statements for the three most recent fiscal years. For Hong Kong companies listing in the US, this means the auditor must be registered with the Public Company Accounting Oversight Board (PCAOB). The S-1 must include a reconciliation from HK GAAP or IFRS to US GAAP if the financials are not already prepared under US GAAP. The reconciliation is typically presented in Note 2 of the financial statements and must show the impact on net income and shareholders’ equity for each period.

The key metric to extract is the “adjustment to revenue recognition.” Under US GAAP (ASC 606), revenue from contracts with customers must be recognised when control transfers, which often differs from HK GAAP’s “risks and rewards” model. A material upward adjustment to revenue in the reconciliation suggests the company was previously recognising revenue later under HK GAAP — a conservative posture. A material downward adjustment suggests the opposite, and warrants scrutiny of the company’s sales cycle and contract terms.

Management’s Discussion and Analysis (MD&A)

Item 7 (MD&A) is the narrative heart of the S-1. Under Regulation S-K Item 303, the MD&A must discuss “known trends and uncertainties” that are reasonably likely to have a material effect on financial condition. This is a higher standard than HKEX’s “Business Review” under the Companies Ordinance (Schedule 5), which requires a “fair review” but does not mandate forward-looking trend analysis.

Hong Kong analysts should focus on three specific MD&A disclosures:

• Non-GAAP financial measures: The SEC requires a reconciliation of each non-GAAP measure (e.g., Adjusted EBITDA, Non-GAAP net income) to the most directly comparable GAAP measure. If the gap between GAAP net income and Non-GAAP net income exceeds 50% of GAAP net income, the company is likely using adjustments to mask core operating losses.
• Liquidity and capital resources: The MD&A must disclose the company’s cash runway — specifically, whether existing cash and the IPO proceeds will fund operations for at least 12 months. A statement that “the company has sufficient liquidity for the next 12 months” without a detailed working capital analysis is insufficient under SEC guidance (Release No. 33-10786).
• Revenue growth drivers: The MD&A must disaggregate revenue by product line, geography, and customer concentration. A single customer representing more than 10% of total revenue must be named (Item 101 of Regulation S-K). For Hong Kong investors comparing with HKEX disclosures, note that HKEX Listing Rule 13.46(2) requires disclosure of any customer representing 30% or more of revenue — a higher threshold.

Corporate Structure and VIE Disclosures

Exhibit 3.1 and the Corporate Chain

Item 9 of the S-1 (Description of Securities) must include the company’s amended and restated memorandum and articles of association (Exhibit 3.1). For Hong Kong-incorporated issuers, this is the equivalent of the company’s constitutional documents filed with the Hong Kong Companies Registry. The S-1 must also disclose the jurisdiction of incorporation for each material subsidiary — typically a Cayman Islands holding company, a Hong Kong operating subsidiary, and one or more PRC subsidiaries under a VIE structure.

The critical exhibit is Exhibit 10.1 (Material Contracts), which contains the VIE agreements — the series of contractual arrangements (exclusive call option, equity pledge, power of attorney, and exclusive technical services agreement) that allow the offshore listed entity to consolidate the financial results of the PRC operating companies without direct equity ownership. The S-1 must disclose whether these VIE agreements have been reviewed by the CSRC and whether they comply with the PRC Foreign Investment Law (effective 1 January 2020).

Shareholder Rights and the “China Clause”

Since the SEC’s 2021 guidance (Release No. 33-11001), the S-1 must include a separate section titled “Description of Securities” that explicitly states whether the company’s corporate structure includes a variable interest entity (VIE). If it does, the S-1 must disclose that the shareholder rights of the VIE are not directly enforceable under PRC law — the investor holds rights only through the contractual arrangements, not through equity ownership. This is a direct parallel to the disclosure requirements under HKEX Listing Rule 18C.03 for Chapter 18C (Specialist Technology Companies) IPOs, which mandate a similar warning for VIE structures.

Hong Kong sponsors should verify that the S-1 includes a specific risk factor stating that “the company may be subject to enforcement actions by the CSRC, the Cyberspace Administration of China, or other PRC regulatory authorities that could materially affect the VIE structure.” The absence of this factor, or its relegation to a general “regulatory risk” paragraph, is a deficiency that the SEC will flag in a comment letter.

Actionable Takeaways

1. Cross-reference the use of proceeds with the MD&A liquidity analysis: If the IPO proceeds are allocated to “working capital” but the MD&A shows a cash runway exceeding 24 months, the company is overcapitalising — a signal that the offering size may be driven by underwriter fees rather than operational need.
2. Verify the PCAOB auditor registration: Confirm that the auditor listed in the S-1 (Item 8) is a PCAOB-registered firm with a current registration status. A non-registered auditor means the financial statements are not in compliance with US securities law and the offering cannot proceed.
3. Read the VIE agreements as exhibits, not summaries: The summary in the S-1 text is a legal narrative. The actual contractual terms — including the trigger events for the equity pledge and the termination provisions in the exclusive technical services agreement — are in Exhibit 10.1. Hong Kong sponsors should treat this exhibit with the same scrutiny as a share purchase agreement in a Hong Kong M&A transaction.
4. Flag any discrepancy between the risk factors and the MD&A: If the risk factors mention “customer concentration” but the MD&A shows a single customer at 25% of revenue without naming them, the S-1 is internally inconsistent. This discrepancy is a common target for SEC comment letters.
5. Track the effective date of EDGAR Next: As of 1 January 2026, all S-1 filings must be submitted in structured XBRL format. For Hong Kong investors, this means the ability to query risk factors, revenue breakdowns, and VIE disclosures programmatically — a significant improvement over the current PDF-based review process. Ensure your data ingestion systems are XBRL-compliant by Q4 2025.